Your browser doesn't support javascript.
loading
CCND1 and FGFR1 gene amplifications are associated with reduced benefit from aromatase inhibitors in metastatic breast cancer.
Aleksakhina, S N; Kramchaninov, M M; Mikushina, A D; Kubrina, S E; Petkau, V V; Ivantsov, A O; Moiseyenko, V M; Imyanitov, E N; Iyevleva, A G.
Afiliação
  • Aleksakhina SN; Laboratory of Molecular Oncology, N.N. Petrov Institute of Oncology, Saint-Petersburg, Russia, 197758.
  • Kramchaninov MM; City Cancer Center, Saint-Petersburg, Russia, 197758.
  • Mikushina AD; Laboratory of Molecular Oncology, N.N. Petrov Institute of Oncology, Saint-Petersburg, Russia, 197758.
  • Kubrina SE; Laboratory of Molecular Oncology, N.N. Petrov Institute of Oncology, Saint-Petersburg, Russia, 197758.
  • Petkau VV; Sverdlovskiy Regional Oncological Hospital, Ekatherinburg, Russia, 620036.
  • Ivantsov AO; Laboratory of Molecular Oncology, N.N. Petrov Institute of Oncology, Saint-Petersburg, Russia, 197758.
  • Moiseyenko VM; City Cancer Center, Saint-Petersburg, Russia, 197758.
  • Imyanitov EN; Laboratory of Molecular Oncology, N.N. Petrov Institute of Oncology, Saint-Petersburg, Russia, 197758.
  • Iyevleva AG; Saint-Petersburg Pediatric Medical University, Saint-Petersburg, Russia, 194100.
Clin Transl Oncol ; 23(4): 874-881, 2021 Apr.
Article em En | MEDLINE | ID: mdl-32880048
PURPOSE: Endocrine therapy is a mainstay for the treatment of hormone receptor-positive breast cancer (BC); however, only a fraction of patients experience a pronounced response to antagonists of estrogen signaling. There is a need to identify predictors for efficacy of this treatment. METHODS: This study included 138 patients with newly diagnosed metastatic BC, who received upfront endocrine therapy. Archival biopsy specimens were tested for CCND1 and FGFR1 gene amplification and mRNA expression by PCR-based methods. RESULTS: CCND1 and FGFR1 amplification was detected in 24 (17.9%) and 28 (20.9%) of 134 evaluable cases, respectively; 9 carcinomas had concurrent alterations of these two genes. Presence of amplification in at least one locus was more common in tumors of higher grade (p = 0.018) and was associated with higher Ki-67 proliferation index (p = 0.036). CCND1 gene amplification was associated with shorter progression-free survival (PFS) in patients receiving aromatase inhibitors (AI) [16.0 months vs. 32.4 months, HR = 3.16 (95% CI 1.26-7.93), p = 0.014]. FGFR1 status did not significantly affect PFS of AI-treated women; however, objective response to AI was observed less frequently in FGFR1-amplified BC as compared to cases with normal FGFR1 copy number [2/15 (13.3%) vs. 22/46 (47.8%), p = 0.031]. Meanwhile, CCND1/FGFR1 gene status did not influence the outcome of tamoxifen-treated patients. CONCLUSION: Presence of CCND1 and/or FGFR1 amplification is associated with worse outcomes of AI therapy in patients with metastatic BC.
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Amplificação de Genes / Ciclina D1 / Inibidores da Aromatase / Receptor Tipo 1 de Fator de Crescimento de Fibroblastos Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Revista: Clin Transl Oncol Ano de publicação: 2021 Tipo de documento: Article País de publicação: Itália
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Amplificação de Genes / Ciclina D1 / Inibidores da Aromatase / Receptor Tipo 1 de Fator de Crescimento de Fibroblastos Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Revista: Clin Transl Oncol Ano de publicação: 2021 Tipo de documento: Article País de publicação: Itália